Genetic Technologies
Fitzroy
About Genetic Technologies
Genetic Technologies is a global molecular diagnostic business with an extensive range of international patents and a portfolio of tests and related services. Our aim is simple: to concentrate on markets where we can establish a long-term dominant position by providing tests that genuinely affect clinical outcomes. We are already the leading non-government genetic testing business in Australia, and through our wholly owned subsidiary Phenogen Sciences, we now have a solid and growing presence in the USA. We remain committed to the development of a global portfolio of cancer management tests. The first of which is the Breast Cancer Risk Assessment Test, BREVAGenTM.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $38.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: nasdaq:GENE
- Website: gtgcorporate.com
- Phone: +61 3 8412 7000
Industries & Categories
Biotechnology, Genetics, Health Care, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/genetic-technologies-2242717 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.